NEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NeoGenomics Inc (NEO) is not a strong buy for a beginner long-term investor at this time. While there are some positive catalysts such as analyst upgrades and growth initiatives, the lack of strong proprietary trading signals, neutral technical indicators, and mixed sentiment from options and trading trends suggest that the stock does not currently present a compelling entry point for long-term investment.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 59.157, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 10.29, and resistance is at 11.644. The stock closed at $10.85, below the pivot point of 10.967, suggesting limited upward momentum.
Analyst upgrades from Leerink and Benchmark with price targets of $25 and $11, respectively, citing strong momentum, profitability, and the launch of high-value NGS products. The company is also optimizing its financial position with a $275 million convertible senior notes offering to fund growth initiatives.
BofA analyst lowered the price target to $11, citing modestly positive results unlikely to change the broader debate. Options sentiment is bearish, and stock trend analysis suggests a slight decline in the short term. No significant hedge fund or insider activity was noted.
No financial data available for the latest quarter, but analysts noted a modest beat in 1Q results, including 23% growth in NGS. The company plans for adjusted EBITDA improvement in the second half of the year.
Analyst sentiment is mixed, with some upgrades and price target increases (e.g., Leerink to $25, Benchmark to $11) and others maintaining neutral ratings (e.g., BofA at $11). The consensus highlights modest beats and growth potential but also notes concerns about broader execution.
